|
|
Vaccine Detail
|
gp100:209-217 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: gp100:209-217 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007492
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: gp100
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth. (NCI04) (NCIT_C2766).
|
| Host Response |
|
|
| References |
NCIT_C2766: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2766]
|
|
